Teva Showcases Global Impact in 2019 Environmental, Social and Governance Progress Report

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200602005410/en/

The report details Teva’s 2019 efforts to lessen the burden of existing and emerging health concerns. The company’s commitment to address such challenges is reflected in its response to COVID-19 in 2020, including its efforts to ensure continuity of medicine supply, prioritize the safety of its employees and work with governments and public health organizations to advance solutions.

“For Teva, ESG means working to improve the health of our patients and communities and running an accountable business,” said Kåre Schultz, President & CEO of Teva. “This report demonstrates our actions to increase access to quality medicines, support our employees, protect the environment and enhance compliance, while keeping patients at the heart of what we do.”

Committed to bringing more quality, affordable treatments to more people, Teva is improving health through its broad portfolio. The company received more than 1,000 approvals for generic medicines and 25 approvals for specialty medicines. Teva also donated $246 million worth of medicines to patients across the globe. With its partners, Teva implemented custom programs for caregivers in seven countries. The company also received awards for efforts to increase access to medicine and public health leadership in supporting patients with multiple chronic conditions.

Teva recognizes its impact on the environment, working to reduce pollution and ensure efficient use of energy and natural resources across its facilities and supply chain. Teva reduced greenhouse gas emissions by 17% from 2017, total waste by 13% from 2018 and total energy consumption by 6% from 2018.

The company prioritizes the safety and well-being of its employees and achieved its best-recorded internal workplace safety performance to date.

As the world faces new health challenges, Teva remains committed to improving the health of the nearly 200 million patients it serves daily—and of communities around the world. Click here to learn more about Teva’s 2019 ESG Progress Report. For more information about Teva’s response to COVID-19, please see Teva’s COVID-19 Updates and Resources.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to impact and effectively execute on our social, economic, environment and governance related strategy and goals; our ability to successfully compete in the marketplace; consolidation of our customer base and commercial alliances among our customers; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; our business and operations in general, including: duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; interruptions in our supply chain, including due to potential effects of the COVID-19 pandemic on our operations and business in geographic locations impacted by the pandemic and on the business operations of our customers and suppliers; adequacy of and our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic, political or economic instability, major hostilities or terrorism; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption sanctions and trade control laws; manufacturing or quality control problems; disruptions of information technology systems; breaches of our data security and privacy; compliance, regulatory and litigation matters, including our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject or delays in governmental processing time including due to modified government operations due to the COVID-19 pandemic and effects on product and patent approvals; governmental investigations; potential liability for patent infringement; product liability claims; and other financial and economic risks including our exposure to currency fluctuations and restrictions; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2019 and subsequent SEC filings, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

IR
United States
Kevin C. Mannix
(215) 591-8912
Ran Meir
972 (3) 926-7516

PR
United States
Doris Li
(973) 265-3752
Israel
Yonatan Beker
972 (54) 888 5898

Source: Teva Pharmaceutical Industries Ltd.

Share this article: